KRAS^G ^12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening.

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) has limited treatment options, emphasizing the urgent need for effective therapies. The predominant driver in PDAC is mutated KRAS proto-oncogene, KRA, present in 90% of patients. The emergence of direct KRAS inhibitors presents a promising avenue for treatment, particularly those targeting the KRAS^G12C mutated allele, which show encouraging results in clinical trials. However, the development of resistance necessitates exploring potent combination therapies. Our objective was to identify effective KRAS^G12C-inhibitor combination therapies through unbiased drug screening. Results revealed synergistic effects with son of sevenless homolog 1 (SOS1) inhibitors, tyrosine-protein phosphatase non-receptor type 11 (PTPN11)/Src homology

SUBMITTER: Tapia Contreras C 

PROVIDER: S-EPMC11792994 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature